A bird in the hand is worth two in the bush.

The classic adage teaches that it is better to have a certain, but perhaps lesser than expected, outcome than the possibility of something greater that may never come. This lesson holds true for dealing with biopharma transactions. The difficulty of managing an offer...

New Horizons of the Regenerative Medicine Space in Japan

Exciting things are happening in Japan in the regenerative medicine space. As people who work in the industry may be aware, in 2014 Japan modified the regulations pertaining to regenerative medicine products through the adoption of the “Pharmaceutical and...

Implications of the US election on the Life Science Industry

After months of long, hard debate, the votes are in and Donald Trump will become the next president of the United States. The result is one that few had predicted, including the markets. The outcome of this election has been closely watched by professionals within the...

Maximizing Buy Side Success as a Smaller Company

Buying development or commercial stage assets is a strategy with the potential to create multiple sources of value for many small to mid-sized companies. Closing a deal on the buy side can create potential short and/or long term revenue growth, create catalysts to...

Creating an Event Horizon for Your Deal

A key hallmark of many of the most exceptional deals that the Locust Walk team have done involves having successfully developed the marketplace in advance of and leading up to a significant corporate milestone.  As advisors, we are often able to more rapidly engage...